skip to primary navigationskip to content

Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

last modified Oct 05, 2016 03:46 PM
Amadeus Capital Partners, the global technology investor, has made an early-stage investment of £1.5 million in ideaSpace alumni Healx, a Cambridge based healthcare company that seeks new uses for existing drugs in the fight against rare diseases.
Healx secures £1.5m from Amadeus Capital and investors to combat rare diseases

Dr Tim Guilliams, Healx CEO

Healx, founded and based in Cambridge, operates in the fast-growing drug ‘repurposing’ sector. The company uses advanced data analytics, including machine learning and computational biology techniques, alongside scientific literature analysis, to identify novel drug applications for rare diseases that afflict some 350 million people worldwide. Their unique model engages directly with patient advocacy groups, allowing them to lead the way in personalised healthcare for rare diseases.

Hermann Hauser, Partner and co-Founder of Amadeus Capital Partners, said, “Healx has taken advances in machine learning, data mining and analytics and combined them with deep pharma and life sciences expertise to address a growing need in the healthcare sector. With huge pressure on R&D budgets, drug repositioning will be essential in the fight against rare diseases. With this investment, Healx will take up a leadership position in the drug repurposing sector, expected to be worth over $31 billion by 2020.”

Healx has a scalable technology platform which allows it to match potential treatments to rare conditions and patients. Thanks to its data mining approach, the company aims to complete its drug repurposing studies within six months, much faster than historical literature-based studies.

While there are around 8,000 rare diseases – disorders affecting fewer than 1 in 2,000 people in Europe – only about 500 have a cure. Many are linked to genetics and children account for some 75% of identified cases. Healx has won contracts from major medical foundations in the US and Europe to find drug candidates to treat conditions including childhood diseases, Barth syndrome and Fragile-X.

Sales of ‘orphan’ drugs designed to treat a specific rare condition have been growing following changes in regulation and tax incentives in the US, with the market forecast to reach $178 billion in 2020. However, as only a small proportion of the population is affected by a particular rare disease, the justification for investing large sums in clinical trials remains a barrier to innovation.

Tim Guilliams, Chief Executive, Healx, commented: “Studies into rare medical conditions have long failed to receive adequate funding. By repurposing existing drugs to combat rare diseases, Healx is able to find potential treatments at a fraction of the cost and in a much shorter timeframe than developing a new drug. With this investment, Healx will have the resources to expand our technology platform and accelerate our drug review process to find treatments to many more devastating illnesses.”

To read more information, click here.

RSS Feed Latest news

Elpis Biomed, GeoSpock and Owlstone Win Cambridge Independent Science and Technology Awards

Nov 04, 2018

Elpis Biomed, based at IdeaSpace South, has scooped 'Start-Up of the Year' award at the Cambridge Independent Science and Technology Awards 2018. ideaSpace alumni Owlstone Medical also took home 'Medtech Company of the Year' and GeoSpock won the 'Technology Company of the Year' award. Congratulations to all!

LESSONS FROM A FOUNDER: Tips for Successful Product Design

Oct 26, 2018

Coming up with an idea for a product is the easy bit - it's the designing of it that can be a complicated and costly process. At a recent ideaSpace event we heard from four founders who offered their insights on how you can build a successful product that your customers are going to love. Read on for tips from our experts.

Camallergy Appoints Baxter Phillips III as CEO

Oct 25, 2018

Camallergy, based at ideaSpace South, a biopharmaceutical company dedicated to providing patient-centric treatments for life-threatening food allergies, has announced the appointment of Baxter Phillips III as Chief Executive Officer. Camallergy co-founder Sherden Timmins continues his executive appointment in the newly created role of Chief Operating Officer.

Mixcloud Strike a Multi-Year Agreement With Universal Music Group 

Oct 19, 2018

ideaSpace West member Mixcloud has signed a deal with the world's largest record label.

Riverlane and dividiti Ring the Bell to Celebrate Hackathon

Oct 18, 2018

ideaSpace West members Riverlane and dividiti celebrate after a successful quantum computing hackathon.

View all news